Value Added Dasatinib

Products

Information

Value added Dasatinib (Teaser attached) Dasatinib is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) Current available products on the market are not completely absorbed by those patients taking Antacids, PPI's (Omerpazole) or with high stomach pH level (achlorhydria) The prescriber or patient does not need to worry about consumption of Omeprazole (PPI) when taking Zentiva?s Dasatinib, which has been proven to deliver clinically effective dose with or without PPI (Omeprazole). The product is available for Co-development for US and for out licensing in selected EU countries. For more details contact Vaibhav Sharma, Head of Value added products (Vaibhav.Sharma@zentiva.com )
Main Categories
Finished Dosage Forms
All Categories
Finished Dosage FormsTablets
Distribution areas
North America (USA, Canada)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)
ZENTIVA / ZENT2U PRAGUE SCIENTIFICZentiva is a producer of high-quality affordable medicines serving patients in Europe and beyond. With a dedicated team of more than 4,500 people and a network of production sites - including flagship sites in Prague, Bucharest and Ankleshwar - Zentiva strives to be the champion of branded and generic medicines in Europe to better support people's daily healthcare needs. At Zentiva it is our aspiration that healthcare should be a right and not a privilege. More than ever, people need better access to high quality affordable medicines and healthcare.

Log in

See all the content and easy-to-use features by logging in or registering!